– Bristol-Myers Squibb Co on Wednesday said U.S. regulators had
declined to approve the use of its experimental treatment for hepatitis
C, daclatasvir, in combination with other antiviral drugs.
Bristol-Myers said it had
initially sought permission from the U.S. Food and Drug Administration
to market the drug, a so-called NS5A inhibitor, in combination with
asunaprevir, one of the New York-based company’s experimental medicines.
Bristol-Myers abandoned its U.S. marketing application for asunaprevir
in October because of potential competition from more potent drugs,
leaving the FDA without data to gauge the effectiveness of daclatasvir
as part of a combination regimen.